Prostate Cancer: Key Takeaways from Cantor's 2nd Annual Oncology Symposium

Research evidence excerpt

Prostate Cancer: Key Takeaways from Cantor's 2nd Annual Oncology Symposium

Biotechnology

EQUITY RESEARCH Industry Report

May 26, 2026

Prostate Cancer: Key Takeaways from Cantor's 2nd

Research Analysts: Annual Oncology Symposium

Prakhar Agrawal

212-610-3614 As part of our 2nd Annual Cantor Oncology Symposium in NYC, we hosted

Prakhar.Agrawal@cantor.com

a prostate cancer panel featuring two highly esteemed KOLs: Dr. Scott Imogen Mansfield

929-545-6495 Tagawa from Weill Cornell (bio) and Dr. David Wise from NYU Langone

Imogen.Mansfield@cantor.com (bio).

Li Watsek

212-915-1221 We discussed the current treatment paradigm and KOLs’ views on several

Li.Watsek@cantor.com pipeline drugs, including Pfizer’s mevrometostat, T-cell engagers, Candel’s

aglatimagene, and radioligand therapies. Below are our top takeaways.

Current treatment dynamics - Bayer's Nubeqa is gaining meaningful share

●ARPIs (androgen receptor pathway inhibitors) will remain an important

target for the foreseeable future across different stages of prostate

cancer. Most newer agents are also being combined with ARPIs.

●ARPI use in earlier lines of therapy continues to increase significantly

in KOLs’ practice, and very few mCRPC (castration-resistant prostate

cancer) patients now have no prior ARPI exposure.

●Darolutamide (Nubeqa; Bayer) is gaining significant market share in

the hormone-sensitive prostate cancer (HSPC) setting among both

urologists and medical oncologists due to its better safety profile.

○Darolutamide has low blood-brain barrier penetration and

limited potential for drug-drug interactions, which may be

advantageous for the metastatic HSPC population, given age-

related comorbidities and polypharmacy requirements.

●KOLs differed on the impact of the OS miss in Ph3 ARANOTE